Dynavax Technologies Corporation
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes o…
Drug Manufacturers - Specialty & Generic
US, EmeryVille [HQ]
DVAX/Financials
Wall Street · Earnings · Institutional Sentiment
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Dynavax Technologies Corporation's gradings, price targets and earnings estimates.
Earnings
See the historical earnings and what wall street
analysts forecasted and
forecast for
future earnings.
Reported
Past Estimate Consensus
Future Estimate Consensus
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2015 | -3.4500 | -3.290 | 11 | 4 | -90 | -423 | -90 | -1 | -91 | -1 | 17 | 4 |
| 2016 | -3.2500 | -3.204 | 4 | 5 | -106 | -412 | -104 | -1 | -105 | -1 | 22 | 5 |
| 2017 | -2.9200 | -1.716 | 11 | 1 | -112 | -220 | -110 | 0.27 | -110 | 0.28 | 37 | 1 |
| 2018 | -1.8100 | -2.515 | 0.33 | 6 | -95 | -140 | -89 | -118 | -94 | -135 | 27 | 6 |
| 2019 | -2.5500 | -2.040 | 8 | 36 | -158 | -262 | -149 | -8 | -153 | -8 | 64 | 35 |
| 2020 | -2.1000 | -0.870 | 35 | 40 | -151 | -64 | -114 | -26 | -121 | -85 | 74 | 39 |
| 2021 | -0.9100 | 0.450 | 46 | 449 | -91 | 103 | -67 | 134 | -75 | 189 | 79 | 153 |
| 2022 | 0.6200 | 1.910 | 439 | 717 | 76 | 343 | 142 | 360 | 133 | 359 | 100 | 153 |
| 2023 | 2.3200 | -0.134 | 722 | 229 | 293 | 17 | 298 | -53 | 282 | -56 | 131 | 169 |
| 2024 | -0.0496 | 0.193 | 232 | 281 | -6 | 24 | 20 | -65 | -25 | -69 | 152 | 275 |
| 2025 | - | 0.366 | - | 336 | - | 54 | - | -78 | - | -82 | - | 329 |
| 2026 | - | 0.463 | - | 381 | - | 2.F11X | - | 2.F111 | - | 2.F1111 | - | 2.F1111 |
| 2027 | - | 0.731 | - | 457 | - | 1.F12X | - | 1.F121 | - | 1.F1211 | - | 1.F1211 |
| 2028 | - | 1.000 | - | 522 | - | 0.F13X | - | 0.F131 | - | 0.F1311 | - | 0.F1311 |
Institutional Sentiment
Wall Street · Earnings · Institutional Sentiment
Morgan Stanley
1Y Ago:
n/a
Prev. Grade
n/a
n/a
JP Morgan Chase
1Y Ago:
n/a
Prev. Grade
n/a
n/a
Citigroup
1Y Ago:
n/a
Prev. Grade
n/a
n/a
Overall Consensus
Grading Consensus
Price Target Consensus
-100.655% $12.29 · MISS
Nov. 6, 2024Price Then
$12.01
Price Target
$24.50
Price Now
$12.21